Galectin Therapeutics Inc (GALT): who owns it and who trades it
As of Nov 16, 2026, GALT insiders reported 44 open-market sales worth $5.2M and 3 purchases worth $22.9K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was 10X Capital Management, LLC (10% owner), with $1.6M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Galectin Therapeutics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns GALT
98 funds and institutions reported GALT shares worth $73.4M at the end of Q2 2026, about 24% of the company. The largest holder is BlackRock, Inc. with 4.5%.
Funds and institutions (13F) 24%Everyone else 76%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 2.99M | 4.54% | $13.9M | +274% |
| Vanguard Capital Management LLC | 2.17M | 3.29% | $10.1M | +10% |
| Geode Capital Management, LLC | 1.31M | 1.99% | $6.1M | +114% |
| Osaic Holdings, Inc. | 1.20M | 1.83% | $5.6M | +7% |
| Marshall Wace, LLP | 831,010 | 1.26% | $3.9M | -32% |
| Wealthspire Advisors, LLC | 721,788 | 1.10% | $3.3M | No change |
| State Street Corp | 567,779 | 0.86% | $2.6M | +120% |
| Commonwealth Equity Services, LLC | 407,113 | 0.62% | $1.9M | +11% |
| Northern Trust Corp | 386,545 | 0.59% | $1.8M | +196% |
| Vanguard Fiduciary Trust Co | 366,476 | 0.56% | $1.7M | +20% |
| Vanguard Portfolio Management LLC | 327,766 | 0.50% | $1.5M | New |
| Two Sigma Investments, LP | 318,245 | 0.48% | $1.5M | -32% |
| LPL Financial LLC | 285,380 | 0.43% | $1.3M | +7% |
| Cambridge Investment Research Advisors, Inc. | 261,296 | 0.40% | $1.2M | +103% |
| Sovran Advisors, LLC | 257,997 | 0.39% | $875K | +0% |
| Geneos Wealth Management Inc. | 240,427 | 0.37% | $1.1M | -0% |
| UBS Group AG | 219,319 | 0.33% | $1M | +22% |
| Retirement Guys Formula LLC | 211,053 | 0.32% | $979K | +13% |
| Citadel Advisors LLC | 198,701 | 0.30% | $922K | -32% |
| Susquehanna International Group, LLP | 177,197 | 0.27% | $822K | -68% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, GALT insiders reported $22.9K of open-market purchases and $5.2M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | Khurram Jamil | Chief Medical Officer | Sale | 16,250 | $5.13 | $83.4K | Form 4 |
| Jun 29, 2026 | Harold H. Shlevin | Director | Sale | 22,268 | $5.04 | $112K | Form 4 |
| Jun 29, 2026 | Khurram Jamil | Chief Medical Officer | Sale | 47,467 | $5.04 | $239K | Form 4 |
| Jun 26, 2026 | Harold H. Shlevin | Director | Sale | 7,732 | $5.00 | $38.7K | Form 4 |
| Jun 26, 2026 | Khurram Jamil | Chief Medical Officer | Sale | 2,037 | $5.00 | $10.2K | Form 4 |
| Jun 26, 2026 | Khurram Jamil | Chief Medical Officer | Sale | 2,533 | $5.00 | $12.7K | Form 4 |
| Jun 23, 2026 | Khurram Jamil | Chief Medical Officer | Sale | 7,557 | $3.14 | $23.7K | Form 4 |
| May 26, 2026 | Khurram Jamil | Chief Medical Officer | Sale | 568 | $3.10 | $1.8K | Form 4 |
| Feb 6, 2026 | Kary Eldred | Director | Purchase | 300 | $2.70 | $810 | Form 4 |
| Jan 6, 2026 | Joel Lewis | CEO | Sale | 37,698 | $3.58 | $135K | Form 4 |
| Jan 6, 2026 | Jack W Callicutt | CFO | Sale | 20,354 | $3.67 | $74.7K | Form 4 |
| Jan 6, 2026 | Khurram Jamil | Chief Medical Officer | Sale | 21,446 | $3.65 | $78.3K | Form 4 |
| Jan 5, 2026 | Joel Lewis | CEO | Sale | 27,731 | $3.91 | $108K | Form 4 |
| Jan 5, 2026 | Jack W Callicutt | CFO | Sale | 25,732 | $3.90 | $100K | Form 4 |
| Jan 5, 2026 | Khurram Jamil | Chief Medical Officer | Sale | 25,499 | $3.90 | $99.4K | Form 4 |
| Jan 2, 2026 | Joel Lewis | CEO | Sale | 18,571 | $4.20 | $78K | Form 4 |
| Jan 2, 2026 | Jack W Callicutt | CFO | Sale | 13,914 | $4.20 | $58.4K | Form 4 |
| Jan 2, 2026 | Khurram Jamil | Chief Medical Officer | Sale | 13,055 | $4.20 | $54.8K | Form 4 |
| Dec 31, 2025 | Khurram Jamil | Chief Medical Officer | Sale | 8,125 | $4.07 | $33.1K | Form 4 |
| Dec 23, 2025 | Kevin D Freeman | Director | Purchase | 5,500 | $3.55 | $19.5K | Form 4 |
| Dec 23, 2025 | Kary Eldred | Director | Purchase | 700 | $3.73 | $2.6K | Form 4 |
| Dec 17, 2025 | Joel Lewis | CEO | Sale | 7,829 | $7.06 | $55.3K | Form 4 |
| Dec 17, 2025 | Khurram Jamil | Chief Medical Officer | Sale | 8,500 | $7.04 | $59.8K | Form 4 |
| Dec 17, 2025 | Khurram Jamil | Chief Medical Officer | Sale | 6,463 | $7.04 | $45.5K | Form 4 |
| Dec 17, 2025 | Khurram Jamil | Chief Medical Officer | Sale | 4,479 | $7.04 | $31.5K | Form 4 |
| Dec 17, 2025 | Harold H. Shlevin | Director | Sale | 4,706 | $7.04 | $33.1K | Form 4 |
| Dec 17, 2025 | Harold H. Shlevin | Director | Sale | 19,793 | $7.04 | $139K | Form 4 |
| Dec 16, 2025 | James C Czirr +2 | 10% owner | Sale | 30,681 | $6.66 | $204K | Form 4 |
| Dec 15, 2025 | Harold H. Shlevin | Director | Sale | 8,417 | $6.30 | $53K | Form 4 |
| Dec 12, 2025 | Harold H. Shlevin | Director | Sale | 19,793 | $6.27 | $124K | Form 4 |
| Dec 9, 2025 | Harold H. Shlevin | Director | Sale | 16,790 | $6.27 | $105K | Form 4 |
| Dec 8, 2025 | Harold H. Shlevin | Director | Sale | 20,000 | $5.96 | $119K | Form 4 |
| Dec 8, 2025 | Harold H. Shlevin | Director | Sale | 35,000 | $5.95 | $208K | Form 4 |
| Dec 8, 2025 | Harold H. Shlevin | Director | Sale | 4,000 | $6.01 | $24K | Form 4 |
| Dec 8, 2025 | Harold H. Shlevin | Director | Sale | 25,000 | $5.95 | $149K | Form 4 |
| Dec 8, 2025 | Harold H. Shlevin | Director | Sale | 35,000 | $6.02 | $211K | Form 4 |
| Dec 8, 2025 | Harold H. Shlevin | Director | Sale | 20,000 | $6.00 | $120K | Form 4 |
| Dec 3, 2025 | 10X Capital Management, LLC +2 | 10% owner | Sale | 132,069 | $5.73 | $757K | Form 4 |
| Dec 3, 2025 | 10X Capital Management, LLC +2 | 10% owner | Sale | 120,000 | $5.73 | $688K | Form 4 |
| Dec 2, 2025 | 10X Capital Management, LLC +2 | 10% owner | Sale | 30,000 | $5.47 | $164K | Form 4 |
| Nov 18, 2025 | Joel Lewis | CEO | Sale | 6,783 | $6.15 | $41.7K | Form 4 |
| Nov 18, 2025 | Jack W Callicutt | CFO | Sale | 18,210 | $6.22 | $113K | Form 4 |
| Nov 18, 2025 | Jack W Callicutt | CFO | Sale | 28,100 | $6.22 | $175K | Form 4 |
| Nov 17, 2025 | Joel Lewis | CEO | Sale | 15,680 | $6.04 | $94.7K | Form 4 |
| Nov 17, 2025 | Jack W Callicutt | CFO | Sale | 9,586 | $6.03 | $57.8K | Form 4 |
| Nov 17, 2025 | Jack W Callicutt | CFO | Sale | 19,701 | $6.03 | $119K | Form 4 |
| Nov 17, 2025 | Jack W Callicutt | CFO | Sale | 2,323 | $6.03 | $14K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| 10X Capital Management, LLC | 10% owner | – | $1.6M | Dec 3, 2025 |
| Harold H. Shlevin | Director | – | $1.4M | Jun 29, 2026 |
| Khurram Jamil | Chief Medical Officer | – | $773K | Jul 14, 2026 |
| Jack W Callicutt | Chief Financial Officer | – | $712K | Jan 6, 2026 |
| Joel Lewis | President and CEO, Director | – | $513K | Jan 6, 2026 |
| James C Czirr | 10% owner | – | $204K | Dec 16, 2025 |
| Kevin D Freeman | Director | $19.5K | – | Dec 23, 2025 |
| Kary Eldred | Director | $3.4K | – | Feb 6, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
GALT short interest
Moderate short interest. 8.9% of GALT shares are sold short: about 1 share in 11. Over the last 12 reports the number of shares short went up 22%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 8.98M GALT shares were sold short, 8.9% of the shares outstanding, down 1.7% from the report before. At the average daily volume of 194,017 shares, buying them all back would take about 46.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 8.98M | 8.90% | -2% | 194,017 | 46.3 |
| Oct 15, 2026 | 9.13M | 9.05% | -1% | 228,416 | 40.0 |
| Sep 30, 2026 | 9.21M | 9.13% | -1% | 273,539 | 33.7 |
| Sep 15, 2026 | 9.34M | 9.26% | +3% | 371,026 | 25.2 |
| Aug 31, 2026 | 9.08M | 9.00% | +1% | 272,112 | 33.4 |
| Aug 14, 2026 | 9.00M | 8.93% | +4% | 417,100 | 21.6 |
| Jul 31, 2026 | 8.70M | 13.21% | +2% | 367,988 | 23.6 |
| Jul 15, 2026 | 8.49M | 12.90% | -5% | 753,508 | 11.3 |
| Jun 30, 2026 | 8.97M | 13.63% | +14% | 1.84M | 4.9 |
| Jun 15, 2026 | 7.87M | 11.95% | +3% | 250,817 | 31.4 |
| May 29, 2026 | 7.66M | 11.64% | +4% | 388,753 | 19.7 |
| May 15, 2026 | 7.36M | 11.18% | -0% | 345,559 | 21.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Galectin Therapeutics company events
Galectin Therapeutics filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Aug 14, 2026.
- Aug 14, 2026ResultsReleased financial results. Filing
- Aug 4, 2026SharesSold new shares outside a public offering. Filing
- Jun 23, 2026AnnouncementShared information with investors. Filing
- May 15, 2026ResultsReleased financial results. Filing
- Mar 31, 2026ResultsReleased financial results. Filing
- Mar 17, 2026LeadershipThe Board of Directors of Galectin Therapeutics Inc. appointed Dr. Henry Brem to serve as a member of the Board of Directors, effective immediately. Filing
- Jan 21, 2026LeadershipAt the recommendation of the Company’s compensation committee, the Company’s board of directors approved a $300,000 cash retention bonus for the Company’s Chief Medical Officer, Dr. Khurram Jamil, and a $150,000 cash retention bonus for the Company’s Chief Financial Officer, Jack Callicutt. Filing
- Jan 12, 2026LeadershipMarc Rubin resigned from the Board of Directors of Galectin Therapeutics, Inc. Filing
- Dec 19, 2025AgreementGalectin Therapeutics Inc. and Richard E. Uihlein entered into a Line of Credit Letter Agreement, pursuant to which the Lender shall provide the Company a line of credit of up to $10.00 million to finance the Company’s working capital needs. Filing
- Dec 8, 2025VoteReported shareholder vote results. Filing
- Dec 3, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Galectin Therapeutics financials
Famous investors that hold GALT
2 of the 50 well-known investors we track reported holding GALT in their latest 13F filing. The largest position is Ken Griffin's, worth $739K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 190,501 | $739K | 0.0% | -4% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 110,575 | $429K | 0.0% | +155% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Galectin Therapeutics Inc (GALT) stock
Who owns the most GALT stock?
The largest reported owner of Galectin Therapeutics Inc (GALT) is BlackRock, Inc., with 4.5% of the company. In total, 98 funds and institutions reported holding GALT at the end of Q2 2026, together about 24% of the shares. See the largest owners.
Are GALT insiders buying or selling?
In the last 12 months, GALT insiders reported 3 open-market purchases worth $22.9K and 44 sales worth $5.2M. The latest trade was on Jul 14, 2026. See every trade.
What is the short interest in GALT?
As of Oct 30, 2026, 8.98M GALT shares were sold short, 8.9% of the shares outstanding, down 1.7% from the report before. At the average daily volume of 194,017 shares, buying them all back would take about 46.3 trading days (days to cover). See the history.
Which famous investors hold GALT?
2 of the 50 well-known investors we track reported GALT in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $739K. See all holders.
Executive pay
Galectin Therapeutics's chief executive was paid a total of $1.2M for the year ended Dec 31, 2025, down 1% from $1.2M the year before. In the last 12 months, Galectin Therapeutics's executives and directors bought $22.9K of stock on the open market and sold $3.4M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.